*Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure
ORIGIN = Outcome Reduction with Initial Glargine Intervention
A randomized study of patients with IFG and/or IGT or early T2DM and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed per discretion of the investigator. Median follow-up: 6.2 years.1,2
aSevere symptomatic hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a BG ≤36 mg/dL or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.
See how Lantus® provides effective, improved glycemic control in diabetes patients.†
†Lantus® Prescribing Information. August 2015.
Lantus® is a once-daily, long-acting insulin.**
**Lantus® Prescribing Information. August 2015.
Lantus® is a basal insulin with demonstrated long-term CV safety data††